Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG-Reference-Cited by-同舟云学术

Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG

Published:2014-01 Issue:1 Volume:65 Page:69-76
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Brausi Maurizio,Oddens Jorg,Sylvester Richard,Bono Aldo,van de Beek Cees,van Andel George,Gontero Paolo,Turkeri Levent,Marreaud Sandrine,Collette Sandra,Oosterlinck Willem

Funder

National Cancer Institute

EORTC Charitable Trust

Publisher

Elsevier BV

Subject

Urology

Reference20 articles.

1. EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder: the 2011 update;Babjuk;Eur Urol,2011

2. A review of current guidelines and best practice recommendations for the management of non muscle-invasive bladder cancer by the International Bladder Cancer Group;Brausi;J Urol,2011

3. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors;Morales;J Urol,1976

4. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials;Sylvester;J Urol,2002

5. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA–T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study;Lamm;J Urol,2000

Cited by 285 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of conduction hyperthermia in the treatment of non-muscle invasive bladder cancer: A systematic review;Urologic Oncology: Seminars and Original Investigations;2024-09

2. Experience of organizing BCG therapy for localized bladder cancer in outpatient cancer care centers;Consilium Medicum;2024-08-30

3. Adverse drug reactions of intravesical instillation therapy for bladder cancer: based on FDA adverse event reporting system;Expert Opinion on Drug Safety;2024-08-22

4. Does radical cystectomy still have a role in BCG-unresponsive nonmuscle invasive bladder cancer?;Current Opinion in Urology;2024-08-20

5. Bacillus Calmette-Guérin (BCG)-Induced Pneumonitis: A Case Report;Cureus;2024-08-16